WO2008108163A1 - ガドリニウム化合物及びｍｒｉ用造影剤 - Google Patents

ガドリニウム化合物及びｍｒｉ用造影剤 Download PDF

Info

Publication number
WO2008108163A1
WO2008108163A1 PCT/JP2008/052727 JP2008052727W WO2008108163A1 WO 2008108163 A1 WO2008108163 A1 WO 2008108163A1 JP 2008052727 W JP2008052727 W JP 2008052727W WO 2008108163 A1 WO2008108163 A1 WO 2008108163A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
sugar
imaging
contrast agent
mri
Prior art date
Application number
PCT/JP2008/052727
Other languages
English (en)
French (fr)
Inventor
Norio Miura
Hidetaka Ninomiya
Original Assignee
Konica Minolta Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konica Minolta Holdings, Inc. filed Critical Konica Minolta Holdings, Inc.
Priority to JP2009502504A priority Critical patent/JPWO2008108163A1/ja
Publication of WO2008108163A1 publication Critical patent/WO2008108163A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Signal Processing (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Medicinal Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

　本発明は、（１）Ｔ１緩和能が高く、少ない投与量でも高感度に造影可能であり、（２）全身血管及び肝臓の造影に優れ、かつ、（３）膵臓の造影にも優れ、（４）さらに２４時間以内に体外に大部分が排泄される安全性を有する新規なガドリニウム化合物、及びそれを含む造影剤を提供する。このガドリニウム化合物は、下記一般式（１）で表されることを特徴とする。 　　【化１】 （式中、Ｇはヒドロキシル基と糖が、糖のアノマー位でエーテル結合を形成した一価の残基を表し、～線は糖のアノマー位の立体配位が、α体及び／またはβ体であることを表し、Ｊは二価のアルキレン基を表す。ｎは１または２を表す。）
PCT/JP2008/052727 2007-03-06 2008-02-19 ガドリニウム化合物及びｍｒｉ用造影剤 WO2008108163A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009502504A JPWO2008108163A1 (ja) 2007-03-06 2008-02-19 ガドリニウム化合物及びｍｒｉ用造影剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-055350 2007-03-06
JP2007055350 2007-03-06

Publications (1)

Publication Number Publication Date
WO2008108163A1 true WO2008108163A1 (ja) 2008-09-12

Family

ID=39738060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052727 WO2008108163A1 (ja) 2007-03-06 2008-02-19 ガドリニウム化合物及びｍｒｉ用造影剤

Country Status (2)

Country Link
JP (1) JPWO2008108163A1 (ja)
WO (1) WO2008108163A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009280540A (ja) * 2008-05-26 2009-12-03 Konica Minolta Holdings Inc ガドリニウム化合物及びｍｒｉ用造影剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513445A (ja) * 1995-02-01 1998-12-22 エピックス メディカル，インコーポレイテッド 延長された血液保持を有する診断画像造影剤
JP2002187948A (ja) * 2000-10-11 2002-07-05 Sumitomo Chem Co Ltd アミド化合物の製造方法
JP2004307356A (ja) * 2003-04-02 2004-11-04 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai 新規なデンドリマーおよび造影剤
WO2005062828A2 (en) * 2003-12-23 2005-07-14 Bracco Imaging S.P.A. New compounds useful as metal chelators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513445A (ja) * 1995-02-01 1998-12-22 エピックス メディカル，インコーポレイテッド 延長された血液保持を有する診断画像造影剤
JP2002187948A (ja) * 2000-10-11 2002-07-05 Sumitomo Chem Co Ltd アミド化合物の製造方法
JP2004307356A (ja) * 2003-04-02 2004-11-04 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai 新規なデンドリマーおよび造影剤
WO2005062828A2 (en) * 2003-12-23 2005-07-14 Bracco Imaging S.P.A. New compounds useful as metal chelators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANAKA H. ET AL.: "Synthesis of DTPA-conjugated (1,4)-linked 2-aminoglycosides varying in the anomeric configuration and their MR1 contrast effect", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 3, no. 18, 2005, pages 3311 - 3328 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009280540A (ja) * 2008-05-26 2009-12-03 Konica Minolta Holdings Inc ガドリニウム化合物及びｍｒｉ用造影剤

Also Published As

Publication number Publication date
JPWO2008108163A1 (ja) 2010-06-10

Similar Documents

Publication Publication Date Title
Deller et al. Ice recrystallisation inhibition by polyols: comparison of molecular and macromolecular inhibitors and role of hydrophobic units
WO2008002573A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
JP2013544242A5 (ja)
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
EP1188437A3 (en) Beta-hydroxybutyric acid or acetoacetic acid or salts or esters therof for use in improving cerebral function
KR20080041244A (ko) 지방 알콜 알콕실레이트를 함유하는 조성물
EP1127572A3 (en) Use of flavones for treating cycloxygenase-2 mediated diseases
WO2006116727A3 (en) Compositions and methods for detection of sirolimus
WO2006099258A8 (en) Tigecycline compositions and methods of preparation
CA2548811A1 (en) Drug and food or drink for improving hyperglycemia
RU2003100532A (ru) Фармацевтические композиции, содержащие соединение соединения dds
US20100168256A1 (en) Use of phosphoric triamides in cleaner and hygiene applications
WO2007085962A3 (en) Novel glycolipid adjuvant compositions
PT1589949E (pt) Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares
WO2008108163A1 (ja) ガドリニウム化合物及びｍｒｉ用造影剤
US5639733A (en) Alkyl glycoside aqueous solution
WO2009114325A3 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
WO2009080699A3 (en) Peg-interferon-beta formulations
WO2008040441A3 (en) Silicon derivatives for pet imaging
MX2007002531A (es) Derivados novedosos de 3,5-seco-4-norcolestan y usos de los mismos.
WO2004039331A3 (en) Cleaner compositions
CA2445651A1 (en) Cathartic composition comprising halogenated prostaglandin derivatives
CN1330310C (zh) 降血压剂及其制备方法
EP1946743A3 (en) Humectant composition
WO2007016121A3 (en) Hydrofluorocarbon refrigerant compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711551

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009502504

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711551

Country of ref document: EP

Kind code of ref document: A1